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ABSTRACT: The spectrum of antibacterial activity for the nucleoside antibiotic FR-900493 (1) can be extended by chemical
modiﬁcations. We have generated a small focused library based on the structure of 1 and identiﬁed UT-17415 (9), UT-17455
(10), UT-17460 (11), and UT-17465 (12), which exhibit anti-Clostridium diﬃcile growth inhibitory activity. These analogues also
inhibit the outgrowth of C. diﬃcile spores at 2× minimum inhibitory concentration. One of these analogues, 11, relative to 1
exhibits over 180-fold and 15-fold greater activity against the enzymes, phospho-MurNAc-pentapeptide translocase (MraY) and
polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA), respectively. The phosphotransferase inhibitor 11 displays
antimicrobial activity against several tested bacteria including Bacillus subtilis, Clostridium spp., and Mycobacterium smegmatis, but
no growth inhibitory activity is observed against the other Gram-positive and Gram-negative bacteria. The selectivity index (Vero
cell cytotoxicity/C. diﬃcileantimicrobial activity) of 11 is approximately 17, and 11 does not induce hemolysis even at a 100 μM
concentration.
■ INTRODUCTION
Clostridium diﬃcile, a Gram-positive bacterium, is transmitted by
the fecal-oral route. C. diﬃcile infection (CDI) can cause illness
ranging from diarrhea, colitis, and toxic inﬂammatory bowel
disease to death. C. diﬃcile has become one of the most common
causes of health care-associated infections in U.S. hospitals.1
Approximately 250 000 people are hospitalized in the U.S. every
year from CDI.2 The infective form of C. diﬃcile is the spore, and
its germination is the ﬁrst committed step in CDI onset. C.
diﬃcile is found in abundance in the environment, and colonizes
in the gut where it produces toxins that cause C. diﬃcile-
associated diarrhea (CDAD).3−5 Frequently, treatment with
broad-spectrum antibiotic(s) has the adverse eﬀect of increasing
the incidence of recurrent CDIs because of the disruption of the
normal balance of gut ﬂora.6 A recently described highly toxic
strain, BI/NAP1/027, exhibits resistance to ﬂuoroquinolones
and produces >20 times more toxins than historical strains.7
Antibiotic treatment of CDI is diﬃcult because of the antibiotic
resistance and bacterial physiology (e.g., spore formation and
protective eﬀects of pseudomembranous colitis).8,9 Currently,
there are only a limited number of drugs available for the
treatment of CDAD.10 Metronidazole and vancomycin are the
primary therapy options for CDI. Vancomycin is recommended
for severe infections that do not respond to metronidazole.
Vancomycin, rifaximin, and ﬁdaxomicin are used in recurrent or
persistent cases.11 For severe recurrent CDIs, fecal microbiota
transplantation, which involves instillation of stool from a healthy
donor into the gastrointestinal (GI) tract of the patient, has been
highlighted to restore the gut microbiome to a healthy state.12 At
therapeutic concentrations, currently available drugs for the
treatment of CDI are not eﬀective in inhibiting the germination
or outgrowth of C. diﬃcile spores. Only ﬁdaxomicin has been
reported to inhibit spore production in C. diﬃcile.13 To date, bile
acid derivatives and a few organic molecules have been studied
for their eﬃcacy in the reduction of spore viability or inhibition of
spore germination.14−19
In our continued eﬀorts to identify strong inhibitors of
bacterial phosphotransferases [phospho-MurNAc-pentapeptide
translocase (translocase I or MraY) and polyprenyl phosphate-
GlcNAc-1-phosphate transferase (WecA)] (Figure 1),20−25 we
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have generated a small focused library based on the structure of
the known MraY inhibitor FR-900493 (1, Figure 2)26 and
assayed against the vegetative and spore forms of a C. diﬃcile
strain. MraY is speciﬁc for UDP-N-acetylmuramyl-pentapeptide
(Park’s nucleotide) forming undecaprenyl diphosphoryl-N-
acetylmuramate-pentapeptide (lipid I). WecA and its homo-
logues (e.g., TagO or TarO) in Gram-negative bacteria are
responsible for the ﬁrst step of wall teichoic acid synthesis that
anchors the phospho-GlcNAc moiety of UDP-GlcNAc to
undecaprenyl phosphate (C55−P). MraY enzymatic activity is
essential for the growth of both Gram-positive and Gram-
negative bacteria, and thus is considered as a target of interest for
the discovery of novel antibacterial agents. The major source of
MraY inhibitors resides in the nucleoside-based antibiotic group.
This group has been subdivided into four classes: tunicamycins,
ribosaminouridines, uridyl peptides, and capuramycins. Analysis
Figure 1. Bacterial phosphotransferases and a human glycosyltransferase. MraY (MurX) is an established drug target for Gram-positive and Gram-
negative bacterial infections. WecA is essential in the growth of Mycobacterium spp. and some Gram-positive bacteria (TagO or TarO). DPAGT1 is a
human glycosyltransferase. Strong inhibition of DPAGT1 may cause cytotoxicity in mammalian cells.
Figure 2. Structures of FR-900493 (1) and representative muraymycins, muraymycin A1 (2) and D1 (3). FR-900493 has only the right half of the
muraymycins (the highlighted portion in blue). The unknown stereochemistries of the 5′- and 6′-positions are determined unequivocally in this study.
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of the pharmacological behaviors observed with several
compounds in these classes shows a broad spectrum of
antibacterial activity, including relevant drug-resistant strains,
and in vivo eﬃcacy without apparent toxicity. Ribosaminouridine
antibiotics, which include muraymycin, liposidomycins, capra-
zamycin, and FR-900493 (1), exhibit the most promising
biological proﬁles.27 On the other hand, essentiality of the
WecA/TagO transferase subfamily is not completely understood
in the growth of many bacteria.28,29 Only a few molecules have
been reported to exhibitWecA inhibitory activity.28,29 Herein, we
report a structure−activity relationship (SAR) obtained from a
small focused library of FR-900493 (1) in a range of enzymes
(MraY, WecA, and AglH) and bacterial growth inhibitory assays.
Eﬃcacy of these new MraY inhibitors against C. diﬃcile spores
along with in vitro toxicity assessments of the selected anti-C.
diﬃcile molecules is discussed.
■ RESULTS AND DISCUSSION
Chemistry and SAR of FR-900493. Aminoribosyl-uridyl
peptide antibiotics such as FR-900493 (1) and muraymycins are
an important class of natural products for the development of
novel antibacterial agents.30,31 Chemical syntheses of 1 and
muraymycin analogues are essential to perform exhaustive SAR
studies.32 Muraymycin A1 (2) is one of the most active members
of this family against both Gram-positive and Gram-negative
bacteria. The fatty acid side chain (R2) of 2 is critical for
antimicrobial activity as muraymycin D1 (3) and the other
related molecules lacking the R2 group are poorly active (Figure
2).25,33 Interestingly, we have demonstrated that muraymycinD1
shows strong bacteriostatic activity against Mycobacterium
tuberculosis by targeting the bacterial phosphotransferases
(MurX and WecA).25 Although FR-900493 (1) possesses only
one half of the structure of the muraymycins, it displays
antistaphylococcal activity [minimum inhibitory concentration
(MIC) 3.13 μg/mL] in vitro and in vivo. The LD50 value of 1 is
over 500 mg/kg, which was determined via intravenous
administrations in mice, indicating that 1 is an ideal scaﬀold to
develop into new antibacterial agents.26 It is interesting to note
that 1 was isolated from the culture broth of Bacillus cereus (no.
2045), whereas other aminoribosyl-uridyl peptide antibiotics
including muraymycins were isolated from Streptomyces spp.31,33
Structurally, the C6′-amino group of FR-900493 is methylated,
whereas O-methylation at the C2″-position is observed in
muraymycin A1 and D1. Absolute stereochemistries at the C5′-
and C6′-positions are speculated to be 5′S and 6′S, respectively,
based on the correlations with stereochemistries of muraymycins
and structurally related molecules, caprazamycins. On the basis
of the proposed structure, FR-900493 was ﬁrst synthesized by
Hirano and co-workers who only reported physical chemistry
data (e.g., NMR and optical rotation) for the synthetic
molecule.34 We have synthesized the four diastereomers of FR-
900493 with respect to the C5′- and C6′-stereocenters according
to the synthetic scheme developed for muraymycin D1 (3)25
with minor modiﬁcations and compared their physical and
biological data with those of the natural product. Chemical shifts
and coupling constants of the 5′S,6′S-diastereomer 1 showed
good agreement with those of the natural FR-900493 (see the
Supporting Information).26 The four diastereomers of FR-
900493 were evaluated against the bacterial phosphotransferases
MraY and WecA (Table 1).29,35
Surprisingly, 1 exhibited a weak MraY inhibitory activity (IC50
25.0 μM)but amoderateWecA inhibitory activity (IC50 5.0 μM).
All unnatural diastereomers (4, 5, and 6) did not display either
MraY or WecA inhibitory activity, even at a 100 μM
concentration. The results of these enzymatic assays unequiv-
ocally determined the absolute stereochemistry of FR-900493 to
be 5′S and 6′S conﬁgurations. We have observed that amidation
of the C6′-carboxylic group in muraymycin D1 (3) does not
decrease theMraY/WecA activity.25 Similarly, FR-900493-amide
(7) exhibited an MraY/WecA inhibitory activity equal to that of
1. The N-methyl group of 1 is essential to inhibit the MraY and
WecA enzymes; the de-N-methyl analogue 8 completely lost the
MraY/WecA inhibitory activities. FR-900493 and its analogues
shown in Table 1 were not eﬀective in killing C. diﬃcile (ATCC
43596) at 25.0 μg/mL or lower concentrations. As exempliﬁed in
the antibacterial activity of the muraymycin family molecules,30
the hydrophobic residues appended on the 3-aminopropylamine
portion play a key role in selectivity and susceptibility against
Table 1. Inhibitory Activity of Bacterial Phosphotransferases (MraY and WecA) and C. diﬃcile Growth by the C5′- and 6′-
Diastereomers of FR-900493a
compound WecA inhibition IC50(μM)
b MraY inhibition IC50 (μM)
c C. diﬃcile ATCC 43596 MIC (μg/mL)d
FR-900493 (1) 5.0 ± 5.44 25.0 ± 8.67 >25.0
5′S,6′R-diastereomer (4) >100 >100 >25.0
5′R,6′S-diastereomer (5) >100 >100 >25.0
5′R,6′R-diastereomer (6) >100 >100 >25.0
FR-900493-amide (7) 5.0 ± 6.34 25.0 ± 9.67 >25.0
8 >100 >100 >25.0
tunicamycin 0.15 ± 7.80 3.38 ± 7.32 >25.0
aWecA and MraY assays (see the Supporting Information). bE. coli WecA-containing membrane was used. cHydrogenivirga spp. MraY was used. dA
microdilution broth method was used.
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bacteria (Figure 2). We have generated a small forced library
based on the core structures of 7 and 8, and the generated
molecules were assayed against C. diﬃcile (ATCC 43596) at a
single concentration of 50.0 μg/mL. Four molecules (9, 10, 11,
and 12) displayed anti-C. diﬃcile activity (Table 2), and suﬃcient
amounts of these molecules were resynthesized for thorough in
vitro proﬁling.
Syntheses of FR-900493 Analogues, 9, 10, 11, and 12.
In our synthesis of muraymycin D1 (3), β-ribosylation of the C2-
ether-protected ribose donor (R1 = Me in 15) and Strecker
reaction with mono-protected 1,3-diaminopropane to form
secondary amine were performed stereoselectively.25 Our revised
synthetic routes for FR-900493 analogues (9−12) are illustrated
in Schemes 1 and 2. The monomethoxytetrachlorodiphenylme-
thoxymethyl (MTPM)-protected uridine 13 was prepared
according to the previously reported procedure.36 The primary
alcohol of 13 was oxidized by a modiﬁed Swern condition to
provide the corresponding aldehyde in a quantitative yield, which
was then subjected to Carreira’s asymmetric alkynylation
reaction using (−)-N-methylephedrine,37 furnishing the (S)-
propargyl alcohol 14 in 80% yield with a selectivity of >98:2. The
stereochemistry of the secondary alcohol of 14 generated via
Carreira’s alkynylation was determined by the advanced
Mosher’s method (see the Supporting Information).38 The
newly devised glycosyl donor 15 was designed to provide β-
riboside whose protecting groups can be deprotected under mild
acidic conditions. N-Iodosuccinimide (NIS)−AgBF4-promoted
ribosylation of (S)-propargyl alcohol 14 with 15 furnished the β-
riboside 16 exclusively in 95% yield.23,25,39 The azido group of 16
was reduced with Zn metal in the presence of aq NH4Cl, and the
generated free-amine was protected with (Boc)2O to furnish 17
in 90−92% overall yield. The alkyne moiety of 17 was subjected
to a three-step procedure (partial reduction with a Lindlar
catalyst, osmylation, and oxidative cleavage with Pb(OAc)4),
providing the crude aldehyde 18. In a systematic screening of
catalysts for Strecker reaction of 18 with the 4-aminobutanamide
derivatives 19 (Scheme 1) or 20 (Scheme 2), it was realized that
(BnO)2P(O)CH2P(O)(OBn)OH provided a ∼4:1 mixture of
the 6′S- and 6′R-diastereomers (21S and 21R) in greater than
80% yield. The desired diastereomer 21S was subjected to
hydration reaction with HgCl2-acetaldoxime to furnish the amide
22 in 95% overall yield. N-methylation of 22 was performed via
reductive amination with paraformaldehyde and NaB(CN)H3 to
aﬀord 23 in 95% yield. Global deprotection of 22 and 23 to form
the desired products 9 and 10, respectively, was performed in a
one-pot two-step reaction using 30% triﬂuoroacetic acid (TFA)
followed by 80% TFA at 40 °C; the crude products were puriﬁed
by C18 reverse-phase high-performance liquid chromatography
(HPLC) (MeOH/H2O = 75:25) to yield 9 and 10 in 85−90%
yield. The stereochemistry of the C6′-stereocenter for 21S
generated via Strecker reaction was unequivocally determined via
its conformational analyses (see the Supporting Information).
Similarly, the analogues 11 and 12 were synthesized with the
primary amine 20 via the synthetic scheme developed for 9 and
10 (Scheme 2).
Enzyme and Bacterial Growth Inhibitory Activities of 9,
10, 11, and 12. Despite the extensive eﬀorts to obtain
membrane fractions from C. diﬃcile (ATCC 43596), we could
not obtain suﬃcient amounts of active C. diﬃcile membrane
containingMraY andWecA homolog. In this study, for assays, we
used puriﬁed MraY from the thermophilic bacterium Hydro-
genivirga (HyMraY) and the active membrane fraction (P-60)
from Escherichia coli. Protein sequence alignment via BLAST40 of
HyMraY and EcWecA against C. diﬃcile (strain F501) revealed
that MraY between Hydrogenivirga spp. and C. diﬃcile showed
57% similarity/38% identity andWecA/putative WecA homolog
between E. coli and C. diﬃcile showed 47% similarity/28%
identity. We previously conﬁrmed that the activities of inhibitor
molecules against MraY and WecA are similar across various
species: Mycobacterium smegmatis, M. tuberculosis, E. coli, and
Hydrogenivirga spp.21,29,35 The synthetic molecules (9, 10, 11,
and 12) were evaluated against the phosphotransferases (MraY
and WecA) and C. diﬃcile strain (ATCC 43596) (Table 2). The
N-methyl analogues, 9 and 12, exhibited weak anti-C. diﬃcile
growth inhibitory activity, although their MraY inhibitory
activities were over 30- and 3-fold, respectively, more potent
than that of FR-900493 (1). In sharp contrast, the de-N-methyl
analogues, 10 and 11, were over 100 and 300-times more potent
in the MraY inhibitory activity than 1. The WecA inhibitory
activity of 11 was ∼15-fold more than that of 1. Therefore, the
anti-C. diﬃcile activity of 11 is likely attributed to the inhibition of
the MraY enzyme. This hypothesis was further supported by the
fact that a selective WecA inhibitor, UT-01320,20 did not inhibit
growth of C. diﬃcile at >50.0 μg/mL concentrations. The
analogue 11 was identiﬁed to be a strong MraY/WecA inhibitor,
whose activity was signiﬁcantly better than that of a known
MraY/WecA inhibitor, tunicamycin.28,29,35 The anti-C. diﬃcile
activity is correlated with the enzyme inhibitory activity of MraY;
10 and 11 displayed MIC values of 12.5 and 3.25 μg/mL,
Table 2. Inhibitory Activity of Bacterial Phosphotransferases
(MraY and WecA) and C. diﬃcile Growth by 9−12a
compound
WecA
inhibition IC50
(μM)b
MraY
inhibition IC50
(μM)c
C. diﬃcile ATCC
43596 MIC
(μg/mL)d
FR-900493 (1) 5.0 ± 5.44 25 ± 8.67 >50.0
UT-17415 (9) 0.85 ± 7.50 0.69 ± 7.32 25.0 ± 7.64
UT-17455 (10) 12.5 ± 6.01 0.25 ± 5.80 12.5 ± 5.93
UT-17460 (11) 0.32 ± 4.09 0.08 ± 4.33 3.25 ± 4.40
UT-17465 (12) 12.3 ± 5.75 7.70 ± 5.47 50.0 ± 5.81
UT-01320 0.035 ± 9.14 >100 >50.0
tunicamycin 0.15 ± 7.80 3.38 ± 7.32 >50.0
vancomycin >50.0 >50.0 2.5 ± 7.25
aWecA and MraY assays (see the Supporting Information). bE. coli
WecA-containing membrane was used. cHydrogenivirga spp. MraY was
used. dA microdilution broth method was used.
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respectively, against C. diﬃcile (e.g., an MIC of 2.50 μg/mL for
vancomycin).
Eﬀect of 9, 10, and 11 on C. diﬃcile Spores. The eﬀect of
9, 10, and 11 on C. diﬃcile spores was determined by counting
colony-forming units (CFUs) of the spore germination on
taurocholate-containing agar plates after the treatment of the C.
diﬃcile spores with these analogues (2×MIC) for 24 h. C. diﬃcile
spores show resistance to most known anti-C. diﬃcile agents.19
Scheme 1. Syntheses of Anti-C. diﬃcile FR-900493 Analogues 9 and 10
Scheme 2. Syntheses of Anti-C. diﬃcile FR-900493 Analogues 11 and 12
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Indeed, in these studies, vancomycin, metronidazole, and
linezolid did not inhibit the spore outgrowth, even at 5× MIC.
On the contrary, the new MraY inhibitors 9, 10, and 11
prevented the outgrowth of the C. diﬃcile spores into colonies at
2× MIC (Figure 3).
Physicochemical Properties and in Vitro Toxicity of 11.
UT-17460 (11) exhibited pharmacological characteristics
superior to those of UT-17455 (10); (1) water solubility of 11
(22.0 mg/mL) is 200 times greater than that of 10 (0.11 mg/
mL), (2) 11 is approximately 8 times less cytotoxic than 10
against Vero cells (African green monkey kidney epithelial cells,
IC50 65.0 μM for 10), and (3) 11 showed relatively low induction
of hemolysis (IC50 205.6 μM), whereas 10 lysed blood cells at a
much lower concentration (IC50 70.0 μM) than 11 (Table 3).
Thus, we selected 11 for further in vitro pharmacological
evaluation. WecA enzyme inhibitors have the potential to
interfere with a human homologue, dolichyl-phosphate GlcNAc-
1-phosphotransferase 1 (DPAGT1), which catalyzes the ﬁrst
step of the proteinN-glycosylation process in humans (Figure 1).
Thus, strong inhibition of DPAGT1 may cause cytotoxicity in
vitro and in vivo.41 We have established a counterselection assay
using a thermophilic dolichyl-phosphate GlcNAc-1-phospho-
transferase (AglH from Methanocaldococcus jannaschii) to assess
the toxicity level of antibacterial phosphotransferase inhibitors
(Table 3). Interestingly, 11 exhibited a relatively stronger AglH
inhibitory activity (IC50 3.61 μM) than 10 and tunicamycin;
however, the IC50 level of 11 against Vero cells was much higher
than those of 10 and tunicamycin. The FR-900493 analogue 11
exhibited low permeability across Caco-2 epithelial monolayers
(Papp rate coeﬃcient < 1 × 10
−6 cm/s) with moderate eﬄux (an
eﬄux ratio of 5.5), predicting that 11 is poorly absorbed from the
GI tract.
Spectrum of Antibacterial Activity of 11. As summarized
in Figure 4, UT-17460 (11) exhibited a very narrow spectrum of
antibacterial activity; 11 also killed the other Clostridium spp.,
Clostridium perfringens (MIC 3.1 μg/mL), Bacillus subtilis (MIC
1.6 μg/mL), and M. smegmatis (MIC 0.2 μg/mL) but did not
inhibit the growth of Lactobacillus spp., Staphylococcus aureus,
Staphylococcus pneumoniae, and all Gram-negative bacteria tested
at 25.0 μg/mL or higher concentrations.
■ CONCLUSIONS
FR-900493 (1) has long been known as an MraY inhibitor for
which we have ﬁrmly established the stereochemistry. In our
thorough enzyme inhibitory assays of the phosphotransferases,
we concluded that the antibacterial activity of 1 is attributed to a
combination of WecA and MraY inhibitory activities, but 1 is a
weak MraY inhibitor (IC50 25.0 μM). Because WecA is not
essential in the growth of many bacteria except for a few
pathogens (e.g., Mycobacterium spp.),28,42 improving MraY
inhibitory activity of 1 should be a beneﬁcial direction to identify
eﬀective antibacterial agents. Stereochemistry of the C5′- and
C6′-positions of 1 is required to be the natural conﬁguration (5′S
and 6′S) to exhibit bacterial growth and MraY/WecA enzyme
inhibitory activities. The C6′-CO2H group of 1 can be masked as
its primary amide without decreasing MraY/WecA activity;
however, the N-methyl group is essential for 1 to display
phosphotransferase inhibitory activities. Muraymycins lack the
N-methyl group but exhibit a strong MraY enzyme inhibitory
activity. Importantly, only the muraymycin analogues having a
hydrophobic side chain [e.g., muraymycin A1 (2)] exhibit a
strong antimicrobial activity. We have generated a small focused
library based on the structures of 7 and 8 and screened against the
Figure 3. Viability of C. diﬃcile (ATCC 43596) spores treated with the
MraY inhibitors, 9, 10, and 11, and representative anti-C. diﬃcile drugs.
The spores treated with molecules (2× or 5×MIC) in a BHI medium or
saline (24 h) were plated on a BHI agar plate containing sodium
taurocholate and incubated anaerobically for 48 h. Vancomycin,
metronidazole, and linezolid were treated with 5× MIC, and 9, 10,
and 11 were treated with 2× MIC. Germinated spores were counted
(CFUs) (p ≤ 0.05).
Table 3. Counterselection Assays Based on Prenyl phosphate-GlcNAc-1-phosphotransferases (WecA vs AglH) and in Vitro
Cytotoxicities
WecA inhibition IC50 (μM)
a
compound E. coli WecA
M. smegmatis
WecA AglH inhibition IC50 (μM)
aM. jannaschiiAglH Vero cells IC50 (μM)
a
hemolysis IC50 (μM) sheep
blooda
UT-17455 (10) 12.5 ± 6.01 12.5 ± 5.42 12.5 ± 5.18 7.08 ± 5.67 70 ± 5.71
UT-17460 (11) 0.32±4.09 0.25±4.84 3.61±4.43 65±4.65 205.8±4.33
tunicamycin 0.15 ± 7.80 0.15 ± 7.22 13.27 ± 8.10 0.12 ± 7.78 15 ± 7.83
aAll assay procedures are described in the Supporting Information.
Figure 4. Antibacterial activity of UT-17460 (11, line in red).
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vegetative form of C. diﬃcile strain (ATCC 43596) under
anaerobic conditions. We identiﬁed four anti-C. diﬃcile FR-
900493 analogues, 9, 10, 11, and 12. These analogues were
resynthesized via the synthetic procedures reported previously
with modiﬁcations of selective ribosylation (14 → 16) and
Strecker reactions (18 → 21 and 24) (Schemes 1 and 2). The
resynthesized analogues were characterized by C. diﬃcile growth
and the bacterial phosphotransferase inhibitory assays. The
analogue 11 exhibited strong MraY/WecA inhibitory activity
(IC50 0.08 and 0.30 μM, respectively) and killed the vegetative
state of C. diﬃcile with an MIC value of 3.25 μg/mL. In vitro
cytotoxicity level of 11 was much lower than those of
tunicamycin and 10; although 11 inhibited AglH at low
concentrations. Toxicity of tunicamycin and 10 in mammalian
cells may be largely due to the membrane disruption as
demonstrated by the hemolysis assay. On the other hand, the
hemolytic activity of 11 is attenuated by the pharmacologically
benign hydrophobic group.43 Interestingly, the MraY inhibitors
9, 10, and 11 inhibited the outgrowth of the C. diﬃcile spores
(endospores) at 2× MIC concentrations (Figure 3). The
inhibitory mechanism of outgrowth of the spores by the MraY
inhibitors is far from completely understood. Recently, a strong
lipid II-binding antibacterial peptide, nisin, was reported to
inhibit the viability of the C. diﬃcile spores at high
concentrations.44 The eﬀect of ﬁdaxomicin was also observed
in the inhibition of the C. diﬃcile spore outgrowth at high
concentrations (4.0−14 μg/mL, MIC90 0.5 μg/mL against
vegetative C. diﬃcile).45 C. diﬃcile spores are metabolically
dormant and are known to exhibit impermeability to a wide range
of organic molecules.46 Thus, organic molecules with a high
molecular mass (e.g., Mw = 881.3 for 11) are not likely to
permeate the spore walls and directly inhibit the viability of the
spores. Certain peptides or nucleoside derivatives are recognized
by the Bacillus anthracis germination machinery, increasing their
susceptibility to geminated spores or outgrowing spores.47,48 On
the other hand, germination machineries of C. diﬃcile spores
remain less well-understood because of the signiﬁcantly lower
levels of homologues of the spore coat proteins than those of
other well-studied bacteria (e.g., B. subtilis and B. anthracis).48
Recent studies demonstrated that C. diﬃcile uses subtilisin-like
serine proteases (Csp) that regulate spore germination.49 In C.
diﬃcile, CspC is likely to transmit the bile acid signal to CspB,
which activates the spore cortex lytic enzyme (i.e., SleC) by
cleavage of pro-SlecC. SlecC alters the structure of the spore
cortex and induces Ca-dipicolinate release, which triggers the
outgrowth of C. diﬃcile spores.50 Our MraY inhibitors may be
involved in the induction from the spore forms to the
germinating state. The germinated or outgrowing spores require
MraY, which will be inhibited by the new inhibitors 9−12. We are
currently evaluating the eﬀectiveness of structurally distinct
MraY inhibitors against the C. diﬃcile spores. Correlation of
nucleoside-based MraY inhibitor and ability of the C. diﬃcile
spore germination are being investigated. In preliminary bacterial
growth inhibitory assays against a series of bacteria, 11 displayed
a very narrow-spectrum antibiotic activity (Figure 4), which is
advantageous in the development of selective anti-C. diﬃcile
agents that do not disrupt the gut microbiota in humans. In
addition, in vitro pharmacokinetic data obtained via the Caco-2
permeability assay may indicate that 11 is poorly absorbed from
the GI tract, which may reduce the toxicity of 11 when given
orally. Pharmacokinetics and oral bioavailability, susceptibility to
clinically isolated C. diﬃcile and in vivo eﬃcacy of 11 (using
preclinical animal models), and selectivity of antibacterial activity
of 11 at higher concentrations (1000 μg/mL) are the object of
future studies.
■ EXPERIMENTAL SECTION
Chemistry: General Information. All chemicals were
purchased from commercial sources and used without further
puriﬁcation unless otherwise noted. Tetrahydrofuran (THF),
CH2Cl2, and N,N-dimethylformamide were puriﬁed via an
Innovative Technology’s Pure-Solve System. All reactions were
performed under an argon atmosphere. All stirring procedures
were performed with an internal magnetic stirrer. Reactions were
monitored by thin-layer chromatography (TLC) using 0.25 mm
coated commercial silica gel plates (EMD, silica gel 60F254). TLC
spots were visualized by UV light at 254 nm or developed with
ceric ammonium molybdate or anisaldehyde or copper sulfate or
ninhydrin solutions by heating on a hot plate. Reactions were
also monitored by using Shimadzu LCMS-2020 with the
following solvents: A: 0.1% formic acid in water and B:
acetonitrile. Flash chromatography was performed with SiliCycle
silica gel (Purasil 60 Å, 230−400 mesh). Proton magnetic
resonance (1H NMR) spectral data were recorded on 400 and
500 MHz instruments. Carbon magnetic resonance (13C NMR)
spectral data were recorded on 100 and 125 MHz instruments.
For all NMR spectra, chemical shifts (δH, δC) were quoted in
parts per million (ppm) and J values were quoted in Hz. 1H and
13C NMR spectra were calibrated with a residual undeuterated
solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3CN: δH
= 1.94 ppm, δC = 1.32 ppm; CD3OD: δH = 3.31 ppm, δC =
49.00 ppm; DMSO-d6: δH = 2.50 ppm, δC = 39.52 ppm; D2O:
δH = 4.79 ppm) as an internal reference. The following
abbreviations were used to designate the multiplicities: s =
singlet, d = doublet, dd = double doublets, t = triplet, q = quartet,
quin = quintet, hept = heptet, m = multiplet, and br = broad.
Infrared (IR) spectra were recorded on a PerkinElmer FT1600
spectrometer. HPLC analyses were performed with a Shimadzu
LC-20AD HPLC system. All compounds were puriﬁed by
reverse HPLC to be ≥95% purity. High-resolution mass
spectrometry (HRMS) data were obtained from a Waters
SYNAPT G2-Si (ion mobility mass spectrometer with nano-
electrospray ionization).
FR-900493 (1). 1H NMR (400 MHz, D2O) δ: 7.79 (d, J = 7.9
Hz, 1H), 5.83 (d, J = 7.8 Hz, 1H), 5.75 (d, J = 2.3 Hz, 1H), 5.20
(s, 1H), 4.33 (dd, J = 2.3, 5.1 Hz, 1H), 4.28 (dd, J = 2.3, 8.4 Hz,
1H), 4.23−4.19 (m, 2H), 4.16 (dd, J = 2.8, 6.1 Hz, 1H), 4.13−
4.07 (m, 2H), 3.49 (d, J = 8.3 Hz, 1H), 3.18 (dd, J = 3.6, 13.7 Hz,
1H), 3.05−3.00 (m, 3H), 2.88−2.83 (m, 1H), 2.64−2.61 (m,
1H), 2.41 (s, 3H), 1.94−1.88 (m, 1H), 1.82−1.78 (m, 1H); 13C
NMR (101 MHz, D2O) δ: 175.72, 171.35, 155.21, 141.90,
110.08, 102.46, 91.42, 83.74, 80.76, 78.53, 75.41, 74.20, 71.41,
71.34, 69.98, 52.35, 41.81, 39.02, 38.65, 24.99; HRMS (ESI+)m/
z: calcd for C20H34N5O11 [M + H], 520.2255; found, 520.2262.
FR-900493-5′S, 6′R-Diastereomer (4). 1H NMR (400 MHz,
D2O) δ: 7.83 (d, J = 8.0Hz, 1H), 5.90 (d, J = 8.3Hz, 1H), 5.73 (d,
J = 2.1 Hz, 1H), 5.25 (s, 1H), 4.36 (d, J = 7.7 Hz, 1H), 4.28−4.19
(m, 2H), 4.18 (d, J = 10.4 Hz, 1H), 4.12−4.06 (m, 2H), 3.45 (d, J
= 10.4 Hz, 1H), 3.32 (dd, J = 14.1, 3.7 Hz, 1H), 3.15 (dd, J = 13.9,
5.6 Hz, 1H), 3.10−3.03 (m, 3H), 2.97−2.87 (m, 1H), 2.59−2.51
(m, 1H), 2.43 (s, 3H), 1.99−1.93 (m, 1H), 1.87−1.77 (m, 1H);
13C NMR (101 MHz, D2O) δ: 175.72, 171.35, 155.21, 141.90,
110.08, 102.46, 91.42, 83.74, 80.76, 78.53, 75.41, 74.20, 71.41,
71.34, 69.98, 52.35, 41.81, 39.02, 38.65, 24.99; HRMS (ESI+)m/
z: calcd for C20H34N5O11 [M + H], 520.2255; found, 520.2272.
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FR-900493-5′R,6′S-Diastereomer (5). 1H NMR (400 MHz,
D2O) δ: 7.68 (d, J = 8.2Hz, 1H), 5.93 (d, J = 8.1Hz, 1H), 5.77 (d,
J = 4.3 Hz, 1H), 5.33 (s, 1H), 4.50−4.44 (m, 3H), 4.20−4.11 (m,
3H), 4.06 (dd, J = 5.2, 4.7 Hz, 1H), 3.61 (d, J = 6.9 Hz, 1H), 3.37
(d, J = 13.2 Hz, 1H), 3.13 (dd, J = 13.2, 8.7 Hz, 1H), 3.06 (t, J =
7.3 Hz, 2H), 2.84 (dt, J = 13.5, 6.6 Hz, 1H), 2.74 (dt, J = 12.8, 6.7
Hz, 1H), 2.44 (s, 3H), 1.89 (dq, J = 13.8, 6.6 Hz, 2H); 13C NMR
(101 MHz, D2O) δ: 175.72, 171.35, 155.21, 141.90, 110.08,
102.46, 91.42, 83.74, 80.76, 78.53, 75.41, 74.20, 71.41, 71.34,
69.98, 52.35, 41.81, 39.02, 38.65, 24.99; HRMS (ESI+) m/z:
calcd for C20H34N5O11 [M + H], 520.2255; found, 520.2251.
FR-900493-5′R, 6′R-Diastereomer (6). 1H NMR (400 MHz,
D2O) δ: 7.67 (d, J = 8.0Hz, 1H), 5.91 (d, J = 8.0Hz, 1H), 5.78 (d,
J = 5.2 Hz, 1H), 5.31 (s, 1H), 4.49−4.44 (m, 1H), 4.43 (t, J = 5.3
Hz, 2H), 4.16−4.07 (m, 3H), 4.05 (t, J = 5.3 Hz, 1H), 3.54 (d, J =
7.3 Hz, 1H), 3.23 (dd, J = 13.3, 3.0 Hz, 1H), 3.10−2.98 (m, 3H),
2.80 (dt, J = 13.3, 6.7 Hz, 1H), 2.67 (dt, J = 13.3, 6.9 Hz, 1H),
2.38 (s, 3H), 1.86 (dq, J = 13.9, 7.1 Hz, 2H); HRMS (ESI+)m/z:
calcd for C20H34N5O11 [M + H], 520.2255; found, 520.2247.
FR-900493-Amide (7). 1H NMR (400 MHz, D2O) δ: 7.83 (d,
J = 8.1 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 5.72 (s, 1H), 5.27 (s,
1H), 4.44−4.37 (m, 1H), 4.32−4.25 (m, 2H), 4.23 (t, J = 6.5 Hz,
1H), 4.20−4.14 (m, 1H), 4.11 (d, J = 8.2 Hz, 1H), 3.68 (dd, J =
16.3, 8.1 Hz, 1H), 3.43 (d, J = 14.0 Hz, 1H), 3.26 (dd, J = 13.6, 5.2
Hz, 2H), 3.07 (t, J = 7.3 Hz, 2H), 3.03−2.95 (m, 1H), 2.64−2.56
(m, 1H), 2.50 (s, 3H), 2.04−1.94 (m, 1H), 1.88−1.79 (m, 1H);
13C NMR (101 MHz, D2O) δ: 175.72, 171.35, 155.21, 141.90,
110.08, 102.46, 91.42, 83.74, 80.76, 78.53, 75.41, 74.20, 71.41,
71.34, 69.98, 52.35, 41.81, 39.02, 38.65, 24.99; HRMS (ESI+)m/
z: calcd for C20H35N6O10 [M + H], 519.2415; found, 519.2432.
De N-Methyl FR-900493 (8). 1H NMR (400 MHz, D2O) δ:
7.78 (d, J = 8.1 Hz, 1H), 5.89 (d, J = 7.8 Hz, 1H), 5.78 (d, J = 3.1
Hz, 1H), 5.22 (s, 1H), 4.40 (dd, J = 5.5, 3.2 Hz, 1H), 4.29 (t, J =
6.3 Hz, 1H), 4.22 (dd, J = 6.8, 5.1 Hz, 1H), 4.18 (t, J = 4.5 Hz,
1H), 4.16−4.08 (m, 3H), 3.59 (d, J = 3.8 Hz, 1H), 3.28 (d, J =
12.6 Hz, 1H), 3.11−3.02 (m, 3H), 2.77 (dt, J = 12.8, 6.8 Hz, 1H),
2.64 (dt, J = 12.7, 7.0 Hz, 1H), 1.83 (quin, J = 7.1 Hz, 2H); 13C
NMR (101 MHz, D2O) δ: 175.72, 171.35, 155.21, 141.90,
110.08, 102.46, 91.42, 83.74, 80.76, 78.53, 75.41, 74.20, 71.41,
71.34, 69.98, 52.35, 39.02, 38.65, 24.99; HRMS (ESI+) m/z:
calcd for C19H33N6O10 [M + H], 505.2258; found, 505.2277.
Synthesis of UT-17415 (9). To a stirred solution of 22 (2.9
mg, 1.6 μmol) in CH2Cl2 (0.70 mL) was added TFA (0.30 mL).
The reaction mixture was stirred for 2 h at room temperature
(rt), and all volatiles were evaporated in vacuo. To a stirred
solution of the crude mixture in H2O (0.2 mL) was added TFA
(0.8 mL). The reaction mixture was stirred for 4 h at 40 °C, and
all volatiles were evaporated in vacuo. The crude mixture was
puriﬁed by silica gel column chromatography (CHCl3/MeOH
80:20 to CHCl3/MeOH/H2O/50% aq ammonia 56:42:7:3) to
aﬀord UT-17415 (9) (1.2 mg, 1.6 μmol, 100%): TLC (n-
butanol/ethanol/CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.55;
HPLC condition, column: Phenomenex Kinetex 1.7 μ XB-C18
100 Å 150 × 2.10 mm column, solvents: 80:20 MeOH/0.05 M
NH4HCO3 in water, UV: 254 nm; [α]D
20 +0.038 (c = 0.12,
methanol); IR (thin ﬁlm) νmax: 3333 (br), 2955, 2926, 2855,
1676, 1541, 1515, 1467, 1413, 1273, 1204, 1135, 1063, 1010, 840,
801, 722 cm−1; 1H NMR (400 MHz, CD3OD) δ: 7.82 (d, J = 8.1
Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.1 Hz, 2H), 5.76
(d, J = 8.0 Hz, 1H), 5.70 (s, 1H), 5.18 (s, 1H), 4.58 (s, 1H), 4.28
(d, J = 9.3 Hz, 1H), 4.21−4.16 (m, 3H), 4.14−4.07 (m, 3H), 3.61
(d, J = 9.4 Hz, 1H), 3.21 (dd, J = 13.6, 3.4 Hz, 1H), 2.83 (td, J =
12.1, 11.7, 5.0 Hz, 1H), 2.57 (t, J = 7.6 Hz, 2H), 2.46 (s, 3H),
2.46−2.40 (m, 2H), 2.00−1.89 (m, 1H), 1.79 (d, J = 12.4 Hz,
1H), 1.63−1.55 (m, 2H), 1.37−1.23 (m, 10H), 0.91−0.87 (m,
3H); 13C NMR (101 MHz, CD3OD) δ: 173.86, 172.29, 142.40,
140.18, 137.30, 129.69 (2C), 121.48 (2C), 112.07, 102.41, 92.48,
84.18, 80.50, 78.40, 76.43, 75.35, 71.95, 70.75, 68.52, 54.47,
39.45, 36.33, 35.02, 33.01, 32.78, 30.29, 30.26, 24.30, 23.70,
14.42; HRMS (ESI+) m/z: calcd for C34H53N6O11 [M + H],
721.3772; found, 721.3761.
Synthesis of UT-17455 (10). To a stirred solution of 21 (7.9
mg, 4.5 μmol) in CH2Cl2 (0.70 mL) was added TFA (0.30 mL).
The reaction mixture was stirred for 1 h at rt, and all volatiles
were evaporated in vacuo. To a stirred solution of the crude
mixture in H2O (0.2 mL) was added TFA (0.8 mL). The reaction
mixture was stirred for 2 h at 40 °C, and all volatiles were
evaporated in vacuo. The crude mixture was puriﬁed by silica gel
column chromatography (CHCl3/MeOH 80:20 to CHCl3/
MeOH/H2O/50% aq ammonia 56:42:7:3) to aﬀord UT-17455
(10) (2.4 mg, 3.4 μmol, 76%): TLC (n-butanol/ethanol/
CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.50; HPLC condition:
column: Phenomenex Kinetex 1.7 μ XB-C18 100 Å 150 × 2.10
mm column, solvents: 80:20 MeOH/0.05 M NH4HCO3 in
water, UV: 254 nm; [α]D
21 +0.538 (c = 0.24, methanol); IR (thin
ﬁlm) νmax: 3302 (br), 2955, 2926, 2855, 1672, 1605, 1542, 1515,
1466, 1412, 1271, 1203, 1185, 1131, 1111, 1062, 1010, 819, 721
cm−1; 1H NMR (400 MHz, CD3OD) δ: 7.77 (d, J = 8.1 Hz, 1H),
7.43 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 5.74 (s, 1H),
5.73 (d, J = 12.6 Hz, 1H), 5.14 (s, 1H), 4.21 (dd, J = 4.7, 4.2 Hz,
1H), 4.19−4.13 (m, 2H), 4.11 (t, J = 4.7 Hz, 1H), 4.08 (s, 2H),
4.02−3.99 (m, 1H), 3.50 (d, J = 8.9 Hz, 1H), 3.24 (d, J = 13.0 Hz,
1H), 3.16−3.09 (m, 1H), 2.73−2.60 (m, 2H), 2.57 (t, J = 7.7 Hz,
2H), 2.43 (dd, J = 7.4, 4.0 Hz, 2H), 1.86 (quin, J = 7.2 Hz, 2H),
1.59 (quin, J = 6.4, 5.7 Hz, 2H), 1.35−1.26 (m, 8H), 0.92−0.87
(m, 3H); 13C NMR (101 MHz, CD3OD) δ: 177.20, 174.18,
166.14, 152.10, 142.63, 140.13, 137.35, 129.68 (2C), 121.45
(2C), 110.58, 102.67, 92.49, 85.22, 80.48, 76.41, 75.02, 72.97,
71.23, 64.28, 43.15, 36.34, 35.45, 33.01, 32.78, 30.29, 26.60,
23.70, 14.42; HRMS (ESI+) m/z: calcd for C33H51N6O11 [M +
H], 707.3616; found, 707.3624.
Synthesis of UT-17460 (11). To a stirred solution of 23 (5.3
mg, 2.7 μmol) in CH2Cl2 (0.70 mL) was added TFA (0.30 mL).
The reaction mixture was stirred for 1 h at rt, and all volatiles
were evaporated in vacuo. To a stirred solution of the crude
mixture in H2O (0.2 mL) was added TFA (0.8 mL). The reaction
mixture was stirred for 2 h at 40 °C, and all volatiles were
evaporated in vacuo. The crude mixture was puriﬁed by silica gel
column chromatography (CHCl3/MeOH 80:20 to CHCl3/
MeOH/H2O/50% aq ammonia 56:42:7:3) to aﬀord UT-17460
(11) (2.2 mg, 2.5 μmol, 91%): TLC (n-butanol/ethanol/
CHCl3/28% aq ammonia 4:7:2:7) Rf = 0.50; HPLC condition:
column, Phenomenex Kinetex 1.7 μ XB-C18 100 Å 150 × 2.10
mm column, solvents: 75:25 MeOH/0.05 M NH4HCO3 in
water, UV: 254 nm; [α]D
21 +0.375 (c = 0.30, methanol); IR (thin
ﬁlm) νmax: 3352 (br), 2932, 1677, 1505, 1270, 1243, 1201, 1136,
1060, 840, 801, 722 cm−1; 1H NMR (400MHz, CD3OD) δ: 7.78
(d, J = 8.1 Hz, 1H), 7.18 (dd, J = 9.0, 3.5 Hz, 4H), 7.00 (dd, J =
16.0, 8.6 Hz, 4H), 5.77 (d, J = 2.9 Hz, 1H), 5.73 (d, J = 8.1 Hz,
1H), 5.14 (s, 1H), 4.57−4.50 (m, 1H), 4.28 (s, 2H), 4.22−4.13
(m, 3H), 4.10 (dd, J = 8.6, 4.4 Hz, 1H), 4.07−3.98 (m, 2H),
3.52−3.46 (m, 3H), 3.44 (d, J = 8.8 Hz, 1H), 3.17 (d, J = 13.0 Hz,
1H), 3.14−3.02 (m, 3H), 2.60 (ddq, J = 18.4, 11.8, 6.9 Hz, 2H),
2.29 (td, J = 7.3, 2.8 Hz, 2H), 2.12 (dd, J = 14.5, 5.6 Hz, 2H),
1.93−1.73 (m, 4H), 1.39−1.25 (m, 2H); 13C NMR (101 MHz,
CD3OD) δ: 175.58, 166.16, 157.62, 152.01, 142.55, 131.22,
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129.62 (2C), 123.56 (2C), 118.11 (2C), 118.07 (2C), 110.51,
102.67, 92.31, 85.27, 81.41, 80.43, 76.47, 75.08, 74.07 (2C),
73.01, 71.26, 64.44, 43.72, 43.62, 34.66, 31.48, 26.89; HRMS
(ESI+)m/z: calcd for C39H51F3N7O13 [M +H], 882.3497; found,
882.3512.
UT-17465 (12). To a stirred solution of 24 (4.7 mg, 2.4 μmol)
in CH2Cl2 (0.70 mL) was added TFA (0.30 mL). The reaction
mixture was stirred for 2 h at rt, and all volatiles were evaporated
in vacuo. To a stirred solution of the crude mixture in H2O (0.2
mL) was added TFA (0.8 mL). The reaction mixture was stirred
for 4 h at 40 °C, and all volatiles were evaporated in vacuo. The
crude mixture was puriﬁed by silica gel column chromatography
(CHCl3/MeOH 80:20 to CHCl3/MeOH/H2O/50% aq ammo-
nia 56:42:7:3) to aﬀord UT-17465 (12) (2.0 mg, 2.2 μmol,
92%): TLC (n-butanol/ethanol/CHCl3/28% aq ammonia
4:7:2:7) Rf = 0.55; HPLC condition: column: Phenomenex
Kinetex 1.7 μ XB-C18 100 Å 150 × 2.10 mm column, solvents:
70:30 MeOH/0.05 M NH4HCO3 in water, UV: 254 nm; [α]D
20
+0.246 (c = 0.24, methanol); IR (thin ﬁlm) νmax: 3276 (br), 2933,
1675, 1505, 1465, 1424, 1271, 1243, 1199, 1111 cm−1; 1H NMR
(400MHz, CD3OD) δ: 7.84 (d, J = 7.7 Hz, 1H), 7.19 (dd, J = 8.5,
3.3 Hz, 4H), 7.01 (dd, J = 13.1, 8.6 Hz, 4H), 5.86 (d, J = 7.8 Hz,
1H), 5.73 (d, J = 2.4 Hz, 1H), 5.16 (s, 1H), 4.54 (tt, J = 7.3, 3.1
Hz, 1H), 4.30−4.25 (m, 3H), 4.26 (d, J = 9.2 Hz, 1H), 4.22−4.05
(m, 6H), 3.70 (d, J = 9.2 Hz, 1H), 3.52−3.44 (m, 2H), 3.09 (ddt,
J = 12.3, 8.6, 4.3 Hz, 2H), 2.91−2.82 (m, 1H), 2.58−2.53 (m,
1H), 2.50 (s, 3H), 2.30 (q, J = 6.9 Hz, 2H), 2.15−2.08 (m, 2H),
1.96−1.82 (m, 3H), 1.81−1.71 (m, 1H), 1.39−1.25 (m, 2H); 13C
NMR (101 MHz, CD3OD) δ: 175.34, 172.18, 157.63, 151.97,
142.38, 131.33, 129.66 (2C), 123.55 (2C), 118.12 (2C), 118.08
(2C), 111.86, 92.05, 84.35, 80.28, 78.36, 76.42, 75.37, 74.08
(2C), 71.54, 70.80, 68.28, 43.73, 39.72, 34.50, 31.48 (2C), 24.52;
HRMS (ESI+) m/z: calcd for C40H53F3N7O13 [M + H],
896.3653; found, 896.3640.
MTPM-Protected Uridine 13. The MTPM-protected uridine
13 was synthesized according to the reported procedure.24,34
TLC (hexane/EtOAc 33:67) Rf = 0.50; [α]D
22 −2.315 (c = 8.98,
CHCl3); IR (thin ﬁlm) νmax: 3478 (br), 3057, 2986, 2940, 1715,
1663, 1598, 1556, 1455, 1374, 1265, 1212, 1066, 1039, 853, 808,
787, 732, 702 cm−1; 1H NMR (400MHz, CDCl3) δ: 7.51 (ddd, J
= 17.3, 8.5, 0.7 Hz, 1H), 7.33−7.27 (m, 2H), 7.18 (ddd, J = 8.8,
6.9, 2.1 Hz, 1H), 6.85 (d, J = 5.1Hz, 2H), 6.51 (d, J = 3.7Hz, 1H),
5.72 (dd, J = 8.1, 4.0 Hz, 1H), 5.60−5.51 (m, 2H), 5.48 (dd, J =
12.6, 2.1 Hz, 1H), 4.95−4.93 (m, 1H), 4.92 (t, J = 2.4 Hz, 1H),
4.30−4.25 (m, 1H), 3.89 (ddd, J = 11.7, 9.1, 2.6 Hz, 1H), 3.82−
3.73 (m, 4H), 1.57 (s, 3H), 1.36 (d, J = 2.4 Hz, 3H); 13C NMR
(101 MHz, CDCl3) δ: 162.10, 162.05, 159.51, 150.97, 150.91,
141.55, 141.31, 136.88, 135.28, 135.22, 134.02, 134.00, 133.84,
133.71, 131.17, 129.38, 126.22, 126.18, 125.44, 125.40, 115.33,
114.29, 114.26, 102.05, 102.01, 97.16, 96.82, 87.15, 87.06, 83.76,
83.65, 80.29, 69.50, 62.76, 62.72, 55.69, 27.25, 25.25; HRMS
(ESI+) m/z: calcd for C27H26N2O8NaCl4 [M + Na], 669.0341;
found, 669.0324.
Propargyl Alcohol 14.To a stirred solution of 13 (1.54 g, 2.37
mmol) and dichloroacetic acid (0.29 mL, 3.56 mmol) in CH2Cl2
(11.9 mL) and DMSO (2.37 mL) was added N,N′-
diisopropylcarbodiimide (0.56 mL, 3.56 mmol) at 0 °C, and
the reaction mixture was warmed to rt. After 8 h, the reaction was
quenched with saturated aq NaHCO3 and extracted with EtOAc.
The combined organic extracts were dried over Na2SO4 and
concentrated in vacuo. The precipitates were ﬁltered, and the
crude mixture was used for the next reaction without puriﬁcation.
To a suspension of Zn(OTf)2 (3.45 g, 9.48 mmol) and (+)-N-
methylephedrine (1.70 g, 9.48 mmol) in toluene (7.1 mL) was
added Et3N (1.32 mL, 9.48 mmol) at rt. After 3 h, 4-phenyl-1-
butyne (1.33 mL, 9.48 mmol) was added. After 4 h, a solution of
the crude aldehyde in toluene (5 mL) was added. The reaction
mixture was stirred for 15 h, quenched with saturated aq
NaHCO3, and extracted with EtOAc. The combined organic
extracts were dried over Na2SO4 and concentrated in vacuo. The
crude mixture was puriﬁed by silica gel column chromatography
(hexane/EtOAc 60:40 to 50:50) to aﬀord 14 (1.48 g, 1.90 mmol,
80% for 2 steps): TLC (hexane/EtOAc 50:50) Rf = 0.30; [α]D
22
−0.116 (c = 2.17, CHCl3); IR (thin ﬁlm) νmax: 3387 (br), 3087,
2981, 2937, 1716, 1664, 1597, 1556, 1454, 1374, 1276, 1211,
1156, 1065, 1039, 916, 856, 807, 786, 733, 698 cm−1; 1H NMR
(400 MHz, CDCl3) δ: 7.53 (ddd, J = 20.4, 8.5, 0.7 Hz, 1H),
7.35−7.27 (m, 4H), 7.24−7.15 (m, 4H), 6.85 (d, J = 5.1 Hz, 2H),
6.51 (d, J = 5.4 Hz, 1H), 5.68 (dd, J = 8.1, 4.1 Hz, 1H), 5.60−5.50
(m, 3H), 4.89−4.78 (m, 2H), 4.57 (ddt, J = 12.0, 4.3, 2.0 Hz,
1H), 4.24 (dd, J = 4.4, 3.1 Hz, 1H), 3.78 (d, J = 3.3 Hz, 3H), 2.83
(t, J = 7.5 Hz, 2H), 2.53 (td, J = 7.4, 2.0 Hz, 2H), 1.57 (s, 3H),
1.36 (s, 3H); 13C NMR (101 MHz, CDCl3) δ: 162.11, 162.08,
159.50, 150.87, 150.85, 141.07, 140.84, 140.30, 140.27, 136.90,
135.36, 135.29, 133.99, 133.95, 133.79, 133.64, 131.21, 129.37,
129.34, 128.41, 128.39, 126.40, 126.21, 126.18, 125.49, 125.44,
115.34, 115.32, 114.28, 114.24, 101.79, 101.74, 96.69, 96.37,
89.23, 89.19, 86.83, 86.73, 84.09, 83.93, 80.91, 69.46, 63.02,
62.99, 55.68, 34.72, 34.70, 27.16, 25.29, 20.87, 20.85; HRMS
(ESI+) m/z: calcd for C37H34N2O8NaCl4 [M + Na], 797.0967;
found, 797.0994.
Ribosylation of 14. To a stirred suspension of 14 (227 mg,
0.292 mmol), 15 (497 mg, 0.584 mmol), MS3Å (900 mg), and
SrCO3 (431 mg, 2.920 mmol) in CH2Cl2 (12.0 mL) were added
AgBF4 (28.5 mg, 0.146 mmol) and NIS (131 mg, 0.584 mmol) at
0 °C. After 24 h, the reaction mixture was added to Et3N (2 mL)
and passed through a silica gel pad (hexane/EtOAc 1:1). The
combined organic phase was concentrated in vacuo. The crude
mixture was puriﬁed by silica gel column chromatography
(hexane/EtOAc 90:10 to 80:20 to 70:30) to aﬀord 16 (416 mg,
0.277 mmol, 95%): TLC (hexane/EtOAc 67:33) Rf = 0.70; [α]D
21
+0.100 (c = 2.09, CHCl3); IR (thin ﬁlm) νmax: 2942, 2892, 2866,
2102, 1743, 1724, 1675, 1600, 1556, 1456, 1382, 1371, 1278,
1218, 1099, 1070, 1049, 1013, 999, 882, 807, 772, 745, 681 cm−1;
1H NMR (400 MHz, CDCl3) δ: 7.54 (dd, J = 23.1, 8.5 Hz, 1H),
7.32−7.27 (m, 4H), 7.24−7.16 (m, 4H), 6.84 (d, J = 7.3 Hz, 2H),
6.51 (d, J = 3.7 Hz, 1H), 5.71−5.64 (m, 2H), 5.60−5.49 (m, 2H),
5.20−5.16 (m, 3H), 4.79 (ddd, J = 7.5, 6.5, 3.1 Hz, 1H), 4.64 (td,
J = 5.9, 2.6 Hz, 1H), 4.57 (ddt, J = 11.4, 6.3, 1.9 Hz, 1H), 4.28 (dt,
J = 6.2, 2.8 Hz, 1H), 4.19 (tt, J = 6.1, 3.0 Hz, 1H), 3.79−3.72 (m,
7H), 3.50 (ddd, J = 13.0, 7.6, 3.3 Hz, 1H), 3.35 (dd, J = 13.0, 3.4
Hz, 1H), 2.83 (t, J = 7.4 Hz, 2H), 2.55 (td, J = 7.4, 1.8 Hz, 2H),
2.29 (t, J = 1.6 Hz, 2H), 2.24 (dd, J = 5.1, 2.1 Hz, 2H), 1.62−1.55
(m, 7H), 1.36 (d, J = 2.0 Hz, 3H), 1.08−1.00 (m, 54H); 13C
NMR (101 MHz, CDCl3) δ: 175.61, 170.98, 170.88, 170.71,
170.70, 170.64, 162.17, 162.14, 159.45, 150.75, 150.72, 140.39,
140.19, 140.15, 140.13, 136.92, 136.91, 135.43, 135.29, 133.94,
133.80, 133.65, 131.24, 129.36, 129.31, 128.46 (2C), 128.40
(2C), 126.46, 126.44, 126.19, 126.10, 125.56, 125.45, 115.29,
115.25, 114.23, 114.22, 104.61, 104.55, 101.83, 101.82, 88.84,
88.20, 84.44, 84.35, 83.93, 81.43, 81.33, 80.57, 79.88, 76.49,
75.86, 75.83, 74.12, 71.78, 71.73, 71.40, 70.73, 69.60, 69.47,
68.85, 68.78, 59.97, 59.96, 55.67, 46.15, 45.97, 44.72, 44.58,
34.65, 34.51, 34.49, 32.67, 32.61, 32.57, 28.00, 27.38, 27.35,
27.30, 27.07, 25.34, 25.27, 20.89, 18.05 (12C), 11.91 (6C);
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HRMS (ESI+) m/z: calcd for C74H106Cl4N5O15Si2 [M + H],
1500.5978; found, 1500.5992.
Synthesis of 17. A suspension of 16 (286 mg, 0.19 mmol),
NH4Cl (305 mg, 5.70 mmol), and Zn (373 mg, 5.70 mmol) in
EtOH/H2O (9:1, 9.5 mL) was stirred at 80 °C for 12 h and
cooled to rt. The precipitates were ﬁltered, and the combined
organic solution was concentrated in vacuo. The crude mixture
was used for the next reaction without puriﬁcation. To a stirred
solution of the crude amide in THF (9.5 mL) were added
saturated aq NaHCO3 (9.5 mL) and Boc2O (124 mg, 0.57
mmol). The reaction mixture was stirred for 6 h at rt, and the
aqueous layer was extracted with EtOAc. The combined organic
extracts were dried over Na2SO4 and concentrated in vacuo. The
crude mixture was puriﬁed by silica gel column chromatography
(hexane/EtOAc 85:15 to 80:20 to 67:33) to aﬀord 17 (258 mg,
0.16 mmol, 86% for 2 steps): TLC (hexane/EtOAc 70:30) Rf =
0.30; [α]D
21 +0.012 (c = 0.90, CHCl3); IR (thin ﬁlm) νmax: 3387
(br), 3090, 2941, 2866, 1742, 1720, 1676, 1600, 1556, 1505,
1456, 1366, 1278, 1219, 1161, 1100, 1070, 1049, 1013, 998, 882,
806, 772, 745, 681 cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.54
(dd, J = 19.9, 8.5 Hz, 1H), 7.33−7.27 (m, 4H), 7.24−7.16 (m,
4H), 6.85 (d, J = 7.3 Hz, 2H), 6.51 (d, J = 4.8 Hz, 1H), 5.72−5.64
(m, 2H), 5.60−5.48 (m, 2H), 5.26 (d, J = 6.0Hz, 1H), 5.17 (d, J =
8.6 Hz, 2H), 5.13−5.08 (m, 1H), 4.82−4.76 (m, 1H), 4.65 (t, J =
7.0 Hz, 1H), 4.51 (dd, J = 13.8, 6.0 Hz, 1H), 4.31−4.26 (m, 1H),
4.23−4.17 (m, 1H), 3.78 (d, J = 2.7 Hz, 3H), 3.74 (d, J = 6.9 Hz,
4H), 3.48−3.40 (m, 1H), 3.36−3.26 (m, 1H), 2.83 (t, J = 7.4 Hz,
2H), 2.56 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 2.6 Hz, 2H), 2.23 (t, J =
3.0Hz, 2H), 1.62−1.55 (m, 7H), 1.42 (s, 9H), 1.37 (d, J = 2.6 Hz,
3H), 1.11−0.99 (m, 54H); 13C NMR (101 MHz, CDCl3) δ:
159.46, 150.79, 136.91, 131.26, 129.33, 128.48 (2C), 128.37
(2C), 126.48, 126.11, 125.44, 115.30, 115.26, 79.95, 59.98, 55.68,
46.42, 46.16, 45.95, 44.83, 44.78, 42.49, 34.51, 34.49, 32.60,
32.55, 31.91, 29.69, 28.71, 28.40, 28.34, 27.37, 27.33, 27.29,
27.26, 27.09, 27.05, 25.36, 22.68, 22.63, 20.87, 18.06 (6C), 17.90
(6C), 14.12, 11.92 (3C), 11.78 (3C); HRMS (ESI+) m/z: calcd
for C79H116Cl4N3O17Si2 [M + H], 1574.6597; found, 1574.6609.
Synthesis of 21S. To a stirred solution of 17 (258 mg, 0.16
mmol) and quinoline (38.7 μL, 0.33 mmol) in EtOAc (50 mL)
andMeOH (50mL) was added Lindlar catalyst (300mg). H2 gas
was introduced, and the reaction mixture was stirred under a H2
atmosphere (600 psi) at rt. The reaction mixture was stirred for
11 h under a H2 atmosphere (600 psi) at rt. The reaction mixture
was ﬁltered through Celite, and the ﬁltrate was washed with 1 N
HCl. The combined organic solution was dried over Na2SO4 and
concentrated in vacuo. The crude mixture was used for the next
reaction without puriﬁcation. To a stirred solution of the crude
mixture in t-BuOH/acetone (1:1, 2.1 mL) were added NMO
(192 mg, 1.64 mmol) and OsO4 (4% in water, 1.04 mL, 0.16
mmol) at rt. After 2 h, the reaction solution was diluted with
EtOAc and quenched with saturated aq NaHCO3/saturated aq
Na2SO3 (2:1). The heterogeneous mixture was stirred for 30 min
and extracted with EtOAc. The combined organic extracts were
dried over Na2SO4 and concentrated in vacuo. The crudemixture
was passed through a silica gel pad (hexane/EtOAc 33:67) to
aﬀord the diols as a diastereomeric mixture. This mixture was
used for the next reaction without further puriﬁcation. To a
stirred solution of the diols (22.1 mg, 0.014 mmol) and NaHCO3
(11.5 mg, 0.14 mmol) in CH2Cl2 (0.7 mL) was added Pb(OAc)4
(12.1 mg, 0.027 mmol) at 0 °C. The reaction mixture was stirred
for 2 h at 0 °C, quenched with saturated aq NaHCO3, and
extracted with EtOAc. The combined organic extracts were dried
over Na2SO4 and concentrated in vacuo. The crude aldehyde 18
was used for the next reaction without puriﬁcation. To a stirred
solution of (BnO)2P(O)−CH2−P(O)(OBn)OH (30.6 mg,
0.069 mmol) in CH2Cl2 (0.4 mL) was added a CH2Cl2 (0.3
mL) solution of 18 and 19. To the reaction mixture was added
TMSCN (17.1 μL, 0.14 mmol) and stirred for 9 h at rt. After
completion, the reactionmixture was quenched with saturated aq
NaHCO3 and extracted with EtOAc. The combined organic
extracts were dried over Na2SO4 and concentrated in vacuo. The
crude product was puriﬁed by silica gel column chromatography
(hexane/EtOAc 80:20 to 60:40) to aﬀord the Strecker products.
To a stirred solution of the desired Strecker product (8.8 mg, 5.0
μmol) in EtOH/H2O (9:1, 0.5 mL) were added HgCl2 (2.7 mg,
0.010 mmol) and acetaldoxime (3.0 μL, 0.050 mmol) at rt. After
being stirred for 6 h at rt, the reaction mixture was concentrated
under reduced pressure. The residue was quenched with
saturated aq NaHCO3 and extracted with CHCl3. The combined
organic extracts were dried over Na2SO4 and concentrated in
vacuo. The crude product was puriﬁed by silica gel column
chromatography (hexane/EtOAc 80:20 to 60:40) to aﬀord 21S
(16.7 mg, 9.49 μmol, 69% for two steps) and 21R (4.1 mg, 2.34
μmol, 17% for two steps): 21S: TLC (hexane/EtOAc 60:40) Rf =
0.40; [α]D
21 +0.075 (c = 0.73, CHCl3); IR (thin ﬁlm) νmax: 3317
(br), 2930, 2865, 1719, 1675, 1600, 1462, 1102, 1071, 882, 772,
683 cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.68 (s, 1H), 7.49
(dd, J = 11.4, 8.8 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.32 (s, 1H),
7.19 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 9.3
Hz, 2H), 6.50 (d, J = 15.4 Hz, 1H), 5.73 (dd, J = 23.0, 8.0 Hz,
1H), 5.59 (d, J = 5.9 Hz, 1H), 5.54 (d, J = 9.4 Hz, 2H), 5.42 (t, J =
10.1 Hz, 1H), 5.25 (s, 1H), 5.08−5.00 (m, 2H), 4.96−4.82 (m,
2H), 4.50−4.45 (m, 1H), 4.25−4.19 (m, 1H), 4.15−4.06 (m,
1H), 3.94−3.83 (m, 1H), 3.80−3.63 (m, 10H), 3.49−3.41 (m,
1H), 3.39−3.31 (m, 1H), 3.03 (dt, J = 12.0, 6.1 Hz, 1H), 2.71−
2.61 (m, 1H), 2.54 (t, J = 7.3 Hz, 2H), 2.51−2.45 (m, 1H), 2.29−
2.17 (m, 4H), 1.67−1.51 (m, 10H), 1.41 (s, 9H), 1.28 (dd, J =
15.7, 8.1 Hz, 10H), 1.05 (s, 42H), 1.01 (s, 6H), 0.95 (s, 6H), 0.87
(t, J = 6.4 Hz, 3H); 13CNMR (101MHz, CDCl3) δ: 170.9, 159.5,
136.9, 136.8, 131.3, 131.2, 129.42, 129.36, 128.84 (2C), 128.82
(2C), 128.80 (2C), 126.4, 126.2, 125.1, 120.09, 120.05, 115.4,
115.31, 115.30, 114.84, 114.81, 84.90, 84.87, 80.84, 80.78, 80.2,
79.8, 79.4, 78.2, 76.1, 74.3, 60.0, 59.9, 55.8, 55.7, 52.0, 46.2, 46.0,
44.83, 44.77, 35.4, 32.56, 32.55, 31.8, 31.5, 29.7, 29.19, 29.16,
28.4, 28.3, 27.3, 27.2, 22.7, 18.1 (12C), 14.1, 11.9 (6C); HRMS
(ESI+) m/z: calcd for C88H135Cl4N6O18Si2 [M + H], 1759.8126;
found, 1759.8135.
21R. TLC (hexane/EtOAc 60:40) Rf = 0.30;
1H NMR (400
MHz, CDCl3) δ: 7.74 (dd, J = 16.8, 11.4 Hz, 1H), 7.51 (dd, J =
11.7, 8.5 Hz, 1H), 7.47−7.29 (m, 3H), 7.23−7.15 (m, 2H), 7.10
(t, J = 9.5 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.49 (d, J = 4.6 Hz,
1H), 5.76 (dd, J = 21.1, 8.1 Hz, 1H), 5.65 (d, J = 23.4 Hz, 1H),
5.56 (d, J = 9.2 Hz, 1H), 5.52 (d, J = 3.9 Hz, 1H), 5.46 (t, J = 10.8
Hz, 1H), 5.40−5.23 (m, 2H), 5.23−5.16 (m, 1H), 5.10−5.05 (m,
1H), 5.02 (s, 1H), 4.90−4.78 (m, 1H), 4.26 (t, J = 6.3 Hz, 1H),
4.21 (d, J = 8.9 Hz, 1H), 3.96−3.89 (m, 1H), 3.80−3.71 (m,
10H), 3.68−3.63 (m, 1H), 3.48−3.39 (m, 1H), 3.04−2.95 (m,
1H), 2.75−2.66 (m, 1H), 2.53 (t, J = 7.7 Hz, 2H), 2.44 (d, J =
12.1 Hz, 1H), 2.37−2.27 (m, 2H), 2.23 (d, J = 14.7 Hz, 2H),
1.65−1.51 (m, 10H), 1.42 (s, 9H), 1.36−1.23 (m, 10H), 1.08−
1.01 (m, 42H), 0.97 (s, 6H), 0.90−0.85 (m, 9H); HRMS (ESI+)
m/z: calcd for C88H135Cl4N6O18Si2 [M + H], 1759.8126; found,
1759.8113.
Synthesis of 22. To a stirred solution of 21S (8.8 mg, 5.0
μmol) in EtOH/H2O (9:1, 0.5 mL) were added HgCl2 (2.7 mg,
0.010 mmol) and acetaldoxime (3.0 μL, 0.050 mmol) at rt. After
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being stirred for 6 h at rt, the reaction mixture was concentrated
under reduced pressure. The residue was quenched with
saturated aq NaHCO3 and extracted with CHCl3. The combined
organic extracts were dried over Na2SO4 and concentrated in
vacuo. The crude product was puriﬁed by silica gel column
chromatography (CHCl3/MeOH 99.5:0.5 to 99.2:0.8 to
98.8:1.2) to aﬀord 22 (7.9 mg, 4.5 μmol, 89%): TLC (CHCl3/
MeOH 95:5) Rf = 0.40; IR (thin ﬁlm) νmax: 3335 (br), 2927,
2865, 1668, 1601, 1460, 1099, 1071, 882, 681 cm−1; 1H NMR
(400MHz, CDCl3) δ: 7.59 (dd, J = 19.5, 8.5 Hz, 1H), 7.40 (d, J =
8.0 Hz, 2H), 7.30 (t, J = 2.6 Hz, 1H), 7.24−7.18 (m, 1H), 7.11 (d,
J = 8.0 Hz, 2H), 6.84 (d, J = 7.2 Hz, 2H), 6.50 (s, 1H), 5.84 (br s,
1H), 5.59−5.47 (m, 3H), 5.26−5.14 (m, 2H), 5.06−4.97 (m,
1H), 4.96−4.87 (m, 1H), 4.84−4.73 (m, 1H), 4.55 (t, J = 5.0 Hz,
1H), 4.28−4.14 (m, 2H), 3.80−3.70 (m, 7H), 3.59−3.46 (m,
1H), 3.41 (brs, 2H), 2.83 (brs, 2H), 2.54 (t, J = 7.7 Hz, 3H),
2.50−2.43 (m, 1H), 2.29−2.21 (m, 4H), 1.99 (brs, 2H), 1.65−
1.53 (m, 10H), 1.43 (s, 9H), 1.35 (d, J = 5.2 Hz, 3H), 1.32−1.24
(m, 10H), 1.05 (d, J = 3.2 Hz, 48H), 1.00−0.97 (m, 6H), 0.87 (t,
J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ: 159.6, 159.5,
136.87, 136.85, 136.4, 135.2, 134.0, 133.64, 133.59, 131.3,
129.42, 129.40, 128.9 (2C), 126.2, 125.3, 120.2, 120.1, 115.4
(2C), 74.5, 60.0, 59.9, 55.73, 55.72, 46.2, 46.1, 46.0, 44.8, 35.4,
32.7, 32.6, 31.8, 31.5, 29.69, 29.67, 29.6, 29.5, 29.4, 29.3, 29.24,
29.16, 29.09, 28.51, 28.49, 28.48, 28.45, 28.43, 28.42, 28.36,
28.33, 28.31, 28.28, 27.33, 27.30, 27.25, 27.2, 25.3, 22.7, 18.1
(12C), 14.1, 11.9 (6C); HRMS (ESI+) m/z: calcd for
C88H137Cl4N6O19Si2 [M + H], 1777.8231; found, 1777.8219.
Synthesis of 23.To a stirred solution of 22 (5.8 mg, 3.3 μmol)
and paraformaldehyde (2.9 mg, 0.098 mmol) in CH3CN (0.5
mL) was added NaB(CN)H3 (6.2 mg, 0.098 mmol). After being
stirred for 4 h at rt, the reaction mixture was quenched with
saturated aq NaHCO3 and extracted with CHCl3. The combined
organic extracts were dried over Na2SO4 and concentrated in
vacuo. The crude product was puriﬁed by silica gel column
chromatography (hexane/EtOAc 40:60) to aﬀord 23 (5.5 mg,
3.1 μmol, 95%): TLC (hexane/EtOAc 33:67) Rf = 0.60; [α]D
21
+0.022 (c = 0.28, CHCl3); IR (thin ﬁlm) νmax: 2932, 2866, 1718,
1672, 1601, 1463, 1101, 1071, 884 cm−1; 1H NMR (400 MHz,
CDCl3) δ: 7.75 (d, J = 17.0 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H),
7.43 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.1 Hz, 1H), 7.30 (s, 2H),
7.20 (dt, J = 8.5, 2.0 Hz, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.85 (s,
2H), 6.51 (d, J = 7.9 Hz, 1H), 6.28 (brs, 1H), 5.95 (d, J = 21.6 Hz,
1H), 5.84−5.78 (m, 1H), 5.74 (d, J = 23.3 Hz, 1H), 5.54 (s, 2H),
5.49 (d, J = 9.6 Hz, 1H), 5.18 (brs, 1H), 5.11 (s, 2H), 5.02 (brs,
1H), 4.88−4.83 (m, 1H), 4.80−4.74 (m, 1H), 4.39−4.31 (m,
2H), 4.24−4.18 (m, 1H), 3.92 (t, J = 5.8 Hz, 1H), 3.78 (s, 3H),
3.74 (q, J = 6.6 Hz, 4H), 3.68−3.63 (m, 1H), 3.50−3.40 (m, 2H),
3.37−3.30 (m, 1H), 2.83−2.74 (m, 1H), 2.68−2.59 (m, 1H),
2.54 (t, J = 7.8Hz, 2H), 2.49 (s, 3H), 2.37 (q, J = 8.0, 7.6 Hz, 2H),
2.29−2.20 (m, 4H), 1.98−1.88 (m, 2H), 1.62−1.52 (m, 6H),
1.40 (s, 9H), 1.36 (brs, 3H), 1.33−1.23 (m, 6H), 1.09−1.01 (m,
48H), 0.98 (s, 6H), 0.87 (t, J = 6.4 Hz, 3H); 13C NMR (101
MHz, CDCl3) δ: 171.0, 162.0, 159.5, 157.1, 136.9, 131.3, 129.4,
128.7 (2C), 119.9 (2C), 115.3, 115.1, 114.2, 70.6, 70.1, 69.9,
67.1, 60.4, 60.1, 59.96, 59.95, 58.9, 55.8, 55.7, 54.4, 54.1, 46.22,
46.16, 46.1, 45.3, 44.9, 44.8, 44.7, 42.3, 41.2, 39.93, 39.86, 39.6,
39.04, 38.97, 35.4, 32.7, 32.64, 32.63, 32.62, 32.58, 31.9, 31.8,
31.7, 31.6, 31.53, 31.48, 29.69, 29.67, 29.6, 29.4, 29.22, 29.17,
28.50, 28.49, 28.4, 27.29, 27.28, 27.21, 27.17, 25.23, 25.20, 22.68,
22.66, 18.1 (12C), 14.1, 11.9 (6C); HRMS (ESI+)m/z: calcd for
C89H139Cl4N6O19Si2 [M + H], 1791.8388; found, 1791.8404.
Synthesis of 24S. To a stirred solution of the diols (32.5 mg,
0.020 mmol) synthesized for 21S and NaHCO3 (16.9 mg, 0.20
mmol) in CH2Cl2 (1.0 mL) was added Pb(OAc)4 (17.9 mg,
0.040 mmol) at 0 °C. The reaction mixture was stirred for 2 h at 0
°C, quenched with saturated aq NaHCO3, and extracted with
EtOAc. The combined organic extracts were dried over Na2SO4
and concentrated in vacuo. The crude aldehyde 18 was used for
the next reaction without puriﬁcation. To a stirred solution of
(BnO)2P(O)−CH2−P(O)(OBn)OH (45.0 mg, 0.10 mmol) in
CH2Cl2 (0.5 mL) was added a CH2Cl2 (0.5 mL) solution of 18
and 20. After 6 h, to the reaction mixture was added TMSCN
(25.2 μL, 0.20 mmol) and stirred for 12 h at rt. After completion,
the reaction mixture was quenched with saturated aq NaHCO3
and extracted with EtOAc. The combined organic extracts were
dried over Na2SO4 and concentrated in vacuo. The crude
product was puriﬁed by silica gel column chromatography
(hexane/EtOAc 80:20 to 60:40) to aﬀord 24S (23.9 mg, 12.0
μmol, 61% for two steps) and 24R (5.1 mg, 2.6 μmol, 13% for
two steps). 24S: TLC (hexane/EtOAc 50:50) Rf = 0.40; [α]D
21
+0.102 (c = 0.75, CHCl3); IR (thin ﬁlm) νmax: 3342 (br), 2941,
2866, 1718, 1675, 1505, 1464, 1243, 1164, 1101, 1071, 883, 772,
688 cm−1; 1H NMR (400 MHz, CDCl3) δ: 7.49 (dd, J = 8.5, 4.3
Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.22−7.11 (m, 7H), 6.94−6.88
(m, 5H), 6.86 (d, J = 6.5 Hz, 2H), 6.50 (d, J = 8.6 Hz, 1H), 6.25−
6.16 (m, 1H), 5.73 (dd, J = 22.2, 8.0 Hz, 1H), 5.60 (t, J = 8.8 Hz,
1H), 5.56−5.41 (m, 3H), 5.21 (d, J = 4.4 Hz, 1H), 5.05−4.98 (m,
2H), 4.94−4.77 (m, 2H), 4.53−4.37 (m, 3H), 4.25−4.16 (m,
2H), 4.05−3.98 (m, 1H), 3.80−3.69 (m, 6H), 3.68−3.63 (m,
1H), 3.56 (dd, J = 17.3, 3.4 Hz, 1H), 3.48 (ddt, J = 11.6, 7.2, 4.0
Hz, 2H), 3.44−3.29 (m, 1H), 3.08 (dq, J = 9.5, 5.3, 4.8 Hz, 2H),
2.95 (dt, J = 11.4, 5.5 Hz, 1H), 2.47 (td, J = 12.0, 11.4, 5.7 Hz,
1H), 2.36−2.14 (m, 5H), 2.13−2.05 (m, 2H), 1.97−1.85 (m,
3H), 1.84−1.75 (m, 1H), 1.58 (t, J = 6.9 Hz, 2H), 1.55−1.50 (m,
4H), 1.40 (s, 9H), 1.33 (d, J = 4.8 Hz, 3H), 1.28−1.23 (m, 3H),
1.08−1.02 (m, 42H), 1.01 (s, 6H), 0.94 (d, J = 2.1 Hz, 6H); 13C
NMR (101 MHz, CDCl3) δ: 172.4, 171.0, 170.9, 159.5, 155.8,
150.9, 150.7, 142.8, 136.9, 136.8, 135.3, 135.1, 134.13, 134.05,
133.86, 133.85, 133.78, 131.2, 131.1, 129.42, 129.37, 129.0,
126.4, 126.2, 125.5, 125.2, 122.5 (2C), 121.8, 119.3, 118.4, 116.8
(2C), 116.6 (2C), 115.4, 115.3, 114.71, 114.66, 106.4, 102.3,
102.2, 84.8, 80.7, 80.6, 79.9, 79.8, 79.3, 76.2, 74.32, 74.30, 72.9,
60.38, 60.35, 60.0, 59.9, 55.72, 55.71, 52.0, 46.6, 46.2, 45.9, 44.84,
44.77, 42.99, 42.96, 42.4, 41.2, 33.53, 33.49, 32.6, 32.5, 30.3, 28.4,
27.3 (2C), 27.17, 27.16, 27.1, 25.4, 18.1 (12C), 14.2, 14.1, 11.91
(3C), 11.90 (3C); HRMS (ESI+) m/z : calcd for
C94H135Cl4F3N7O20Si2 [M + H], 1934.8007; found, 1934.8021.
24R: TLC (hexane/EtOAc 60:40) Rf = 0.30;
1H NMR (400
MHz, chloroform-d) δ: 7.53 (d, J = 8.7 Hz, 1H), 7.33−7.29 (m,
1H), 7.21−7.07 (m, 7H), 6.94−6.88 (m, 5H), 6.85 (d, J = 6.8 Hz,
2H), 6.54 (s, 1H), 5.71 (d, J = 7.9 Hz, 1H), 5.58−5.49 (m, 3H),
5.46 (t, J = 8.9 Hz, 1H), 5.24−5.20 (m, 1H), 5.15−5.08 (m, 1H),
5.08−5.00 (m, 1H), 4.92 (dd, J = 11.5, 5.6 Hz, 1H), 4.85−4.78
(m, 1H), 4.49−4.39 (m, 2H), 4.39−4.18 (m, 3H), 3.98 (dd, J =
11.1, 5.4 Hz, 1H), 3.81−3.70 (m, 6H), 3.69−3.61 (m, 2H),
3.52−3.43 (m, 2H), 3.37−3.32 (m, 1H), 3.08 (ddd, J = 12.4, 8.5,
3.8 Hz, 2H), 2.99−2.91 (m, 1H), 2.65 (dd, J = 12.8, 6.5 Hz, 1H),
2.31−2.18 (m, 5H), 2.13−2.04 (m, 2H), 1.96−1.85 (m, 4H),
1.67−1.52 (m, 6H), 1.40 (s, 9H), 1.38−1.29 (m, 3H), 1.25 (s,
6H), 1.10−0.98 (m, 42H), 0.97 (s, 6H), 0.88 (t, J = 6.7 Hz, 3H);
HRMS (ESI+) m/z: calcd for C94H135Cl4F3N7O20Si2 [M + H],
1934.8007; found, 1934.8000.
Synthesis of 25. To a stirred solution of 24S (15.4 mg, 8.0
μmol) in EtOH/H2O (9:1, 0.5 mL) were added HgCl2 (4.3 mg,
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0.016 mmol) and acetaldoxime (4.9 μL, 0.080 mmol) at rt. After
being stirred for 6 h at rt, the reaction mixture was concentrated
under reduced pressure. The residue was quenched with
saturated aq NaHCO3 and extracted with CHCl3. The combined
organic extracts were dried over Na2SO4 and concentrated in
vacuo. The crude product was puriﬁed by silica gel column
chromatography (CHCl3/MeOH 99.5:0.5 to 99.2:0.8 to
98.8:1.2) to aﬀord 25 (15.3 mg, 7.8 μmol, 98%): TLC
(CHCl3/MeOH 95:5) Rf = 0.30; [α]D
21 +0.144 (c = 0.53,
CHCl3); IR (thin ﬁlm) νmax: 3335 (br), 2940, 2866, 1719, 1676,
1505, 1464, 1367, 1242, 1162, 1101, 1070, 882, 681 cm−1; 1H
NMR (400 MHz, CDCl3) δ: 7.53 (dd, J = 8.6, 5.1 Hz, 1H), 7.30
(s, 1H), 7.28−7.22 (m, 2H), 7.21−7.12 (m, 6H), 6.91 (d, J = 8.5
Hz, 4H), 6.86 (d, J = 2.6 Hz, 2H), 6.51 (d, J = 8.7 Hz, 1H), 5.94
(brs, 1H), 5.79−5.67 (m, 3H), 5.56−5.47 (m, 2H), 5.17 (brs,
1H), 5.06 (s, 1H), 4.96 (brs, 1H), 4.82−4.73 (m, 2H), 4.43 (tt, J
= 7.8, 3.8 Hz, 1H), 4.39−4.28 (m, 3H), 4.21 (brs, 1H), 4.13 (brs,
1H), 3.78 (s, 3H), 3.73 (q, J = 7.4 Hz, 5H), 3.67 (brs, 1H), 3.48
(ddd, J = 11.7, 7.2, 3.7 Hz, 2H), 3.41−3.28 (m, 1H), 3.17 (s, 1H),
3.09 (ddd, J = 12.2, 8.2, 3.3 Hz, 2H), 2.80−2.60 (m, 2H), 2.38−
2.15 (m, 7H), 2.13−2.05 (m, 2H), 1.93 (ddd, J = 12.8, 8.0, 3.7
Hz, 2H), 1.85−1.79 (m, 2H), 1.54 (s, 3H), 1.42 (s, 9H), 1.34 (s,
3H), 1.04 (d, J = 2.8 Hz, 42H), 1.01 (s, 6H), 0.96 (s, 6H); 13C
NMR (101 MHz, CDCl3) δ: 162.1, 162.0, 159.6, 159.5, 156.2,
155.8, 150.9, 150.4, 142.80, 142.78, 136.88, 136.86, 135.23,
135.21, 133.9, 133.6, 131.33, 131.30, 131.29, 129.40, 129.37,
129.2, 129.1, 129.02, 128.98, 126.24, 126.22, 126.21, 125.40,
125.36, 124.5, 124.4, 123.20, 123.19, 122.5 (2C), 121.8, 120.1,
119.3, 116.8 (2C), 115.4, 80.4, 80.02, 79.99, 79.96, 79.95, 79.92,
79.87, 79.85, 79.83, 74.51, 74.50, 72.7, 70.4, 70.3, 69.5, 60.0, 59.9,
55.73, 55.72, 46.7, 46.19, 46.15, 46.13, 46.11, 46.10, 46.07, 46.0,
44.8, 34.7, 34.5, 32.61, 32.58, 30.2, 29.7, 29.64, 29.60, 28.50,
28.45, 28.42, 28.38, 28.34, 27.25 (2C), 27.19, 27.16, 25.31, 25.29,
25.27, 18.1 (12C), 14.1, 12.2, 11.9 (6C); HRMS (ESI+) m/z:
calcd for C94H137Cl4F3N7O21Si2 [M + H], 1952.8112; found,
1952.8098.
Synthesis of 26.To a stirred solution of 25 (7.8 mg, 4.0 μmol)
and paraformaldehyde (3.6 mg, 0.12 mmol) in CH3CN (0.5 mL)
was added NaB(CN)H3 (7.5 mg, 0.12 mmol). After being stirred
for 17 h at rt, the reaction mixture was quenched with saturated
aq NaHCO3 and extracted with CHCl3. The combined organic
extracts were dried over Na2SO4 and concentrated in vacuo. The
crude product was puriﬁed by silica gel column chromatography
(hexane/EtOAc 33:67) to aﬀord 26 (4.7 mg, 2.4 μmol, 59%):
TLC (hexane/EtOAc 20:80) Rf = 0.50;
1H NMR (400 MHz,
chloroform-d) δ: 7.57 (d, J = 8.8 Hz, 1H), 7.38 (dd, J = 19.7, 7.9
Hz, 1H), 7.29 (s, 1H), 7.22−7.10 (m, 5H), 6.90 (d, J = 9.1 Hz,
4H), 6.85 (d, J = 3.6 Hz, 2H), 6.51 (d, J = 5.1 Hz, 1H), 6.25 (d, J =
27.7 Hz, 1H), 5.84 (dd, J = 13.4, 8.0 Hz, 1H), 5.55 (s, 1H), 5.48
(brs, 1H), 5.13 (brs, 1H), 5.09 (s, 1H), 4.99 (brs, 1H), 4.86 (d, J
= 6.3 Hz, 1H), 4.74 (d, J = 7.0 Hz, 1H), 4.43 (tt, J = 7.5, 3.6 Hz,
1H), 4.36−4.28 (m, 4H), 4.20 (dd, J = 8.6, 3.5 Hz, 1H), 3.77 (s,
3H), 3.74 (t, J = 6.5 Hz, 4H), 3.69−3.63 (m, 2H), 3.51−3.42 (m,
4H), 3.29 (d, J = 14.5 Hz, 1H), 3.08 (ddd, J = 12.2, 8.4, 3.4 Hz,
2H), 2.76−2.68 (m, 1H), 2.61−2.51 (m, 1H), 2.45 (s, 3H),
2.29−2.14 (m, 5H), 2.12−2.05 (m, 2H), 1.96−1.83 (m, 4H),
1.55 (s, 3H), 1.39 (s, 9H), 1.37 (s, 3H), 1.26 (s, 3H), 1.04 (d, J =
4.6 Hz, 42H), 1.01 (s, 6H), 0.99 (s, 6H); 13C NMR (101 MHz,
CDCl3) δ: 173.0, 172.3, 171.22, 171.15, 162.0, 159.5, 157.5,
155.8, 150.6, 142.83, 142.81, 136.9, 135.4, 131.3, 129.36, 129.35,
129.31, 129.30, 129.03, 128.99, 128.95, 128.93, 126.1, 122.5
(2C), 116.8 (2C), 116.6, 115.33, 115.29, 107.3, 106.9, 84.1,
79.30, 79.28, 79.26, 79.24, 79.23, 74.88, 74.87, 73.6, 72.83, 72.80,
70.61, 70.56, 69.8, 67.3, 60.39, 60.36, 60.0, 59.9, 55.70 (2C), 54.2,
46.6 (2C), 46.1, 46.0, 45.0, 44.9, 44.7, 43.1, 41.2, 32.61, 32.59,
30.33 (2C), 30.27, 30.25, 29.69, 29.67, 29.65, 29.60, 28.52, 28.45,
27.31, 27.28, 27.24, 27.23, 27.22, 27.15, 25.14, 25.11, 22.7, 18.1
(12C), 14.2, 14.1, 11.9 (6C); HRMS (ESI+) m/z: calcd for
C95H139Cl4F3N7O21Si2 [M + H], 1966.8269; found, 1966.8288.
MIC Assays. M. smegmatis (ATCC 607), Klebsiella pneumo-
niae (ATCC 8047), Pseudomonas aeruginosa (ATCC 27853),
Acinetobacter baumannii (ATCC 19606), S. aureus (BAA-1683),
C. diﬃcile (ATCC 43596), Enterococcus faecium (ATCC 349),
Fusobacterium periodontium ATCC 33693), Bacteroides fragilis
(ATCC 25285), Streptococcus pneumoniae (ATCC 6301),
Bacillus subtilis (ATCC 6051), C. perfringens (ATCC 13124),
Lactobacillus casei (ATCC 393), Lactobacillus acidophilus (ATCC
4356), and E. coli (ATCC 10798) were obtained from American
Type Culture Collection (ATCC). A single colony of M.
smegmatis was obtained on Difco Middlebrook 7H10 nutrient
agar enriched with albumin, dextrose, and catalase. Single
colonies of P. aeruginosa, K. pneumoniae, A. baumannii, S. aureus,
E. faecium, and E. coli were grown on tryptic soy agar for 24 h at
37 °C in a static incubator and cultured in tryptic soy broth until
log phase to be an optical density (OD) of 0.2−0.5. The OD was
monitored at 600 nm using a 96-well microplate reader. A single
colony of C. diﬃcile was obtained on a brain−heart infusion
(BHI) agar plate and incubated at 37 °C under anaerobic
conditions for 48 h. Seed cultures and larger cultures were
obtained using a BHI broth. The ﬂasks were incubated
anaerobically for 48 h at 37 °C and cultured to mid-log phase
(OD600 0.4). The other bacteria were cultured in the
recommended conditions by ATCC.48 The inhibitors were
dissolved in polyethylene glycol 300−H2O (1/1, a ﬁnal
concentration of 1 mg per 100 μL). This concentration was
used as the stock solution for all studies. Bacterial cultures were
treated with serial dilutions of inhibitors and incubated at 37 °C
for 48 h. The MIC was determined by a 96-well plate reader
(BioTek Synergy XT,Winooski, VT, USA) at 570 and 600 nm. If
necessary, viable bacteria in each well (96-well plate) were
measured via CFUs on a BHI agar plate. The absorbance
measurements were also performed using a BioTek Synergy XT
(Winooski, VT, USA) 96-well plate reader at 570 and 600 nm.
Cytotoxicity Assays. Cytotoxicity assays were performed
using Veromonkey kidney (ATCCCCL-81) andHepG2 human
hepatoblastoma cell (ATCC HB-8065) lines. Vero or HepG2
cells were cultured in 75 cm2 ﬂasks and transferred to 96-well cell
culture plates using ATCC-formulated Eagle’s minimum
essential medium containing 10% fetal bovine serum and
penicillin−streptomycin. Serially diluted aliquots of each test
compound at concentrations ranging from 0.78 to 200 μg/mL
were added to the cells. Control compounds with known toxicity,
such as tunicamycin, colistin, or tobramycin, were included on
each plate. The plates were incubated, and cytotoxic eﬀects were
determined via the MTT assay.
Spore Preparation. C. diﬃcile (ATCC 43596) was
inoculated on a BHI agar plate and incubated at 37 °C under
anaerobic conditions for 14 days. The spores were collected from
the agar using sterile distilled water and puriﬁed according to the
procedures described in the literature.17 The vegetative forms of
C. diﬃcile were killed upon heating at 50 °C for 30 min. The
prepared spores were suspended in sterile distilled water at 4 °C.
Spore Viability Testing. A solution of test compound was
added to a suspension containing C. diﬃcile spores (2 × 105
mL−1), and the mixture was incubated at 37 °C for 24 h. The
spore suspension treated with the test compound was
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centrifuged (4700g), and the pellet was washed with sterile
distilled water, plated on a BHI agar containing 0.1% sodium
taurocholate (a germination agent), incubated at 37 °C for 48 h
under anaerobic conations. The resulting colonies were counted.
MraY (MurX),WecA, andAglHAssays. Preparations of the
membrane fractions from E. coli, M. smegmatis, and Hydro-
genivirga spp. were performed according to the procedures
previously described.27,33 Procedures for the puriﬁcation of
MraY and AglH and inhibitory assays using these phospho-
transferases are described in the Supporting Information.
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■ ABBREVIATIONS
THF, tetrahydrofuran; TFA, triﬂuoroacetic acid; CH2Cl2,
methylene chloride; DMSO, dimethyl sulfoxide; DMF, N,N-
dimethylformamide; MeOH, methanol; EtOAc, ethyl acetate;
CHCl3, chloroform; HRMS, high-resolution mass spectrometry;
HPLC, high-performance liquid chromatography; TLC, thin-
layer chromatography; Bu, n-butyl; Ts, p-toluenesulfonyl;
DMAP,N,N-dimethyl-4-aminopyridine; Boc, tert-butoxycarbon-
yl; EDCI, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hy-
drochloride; DIC, N,N′-diisopropylcarbodiimide; NIS, N-
iodosuccinimide; NMO, N-methylmorpholine; TIPS, triisopro-
pylsilyl; Ph, phenyl; ATCC, American Type Culture Collection;
MIC, minimum inhibitory concentration; FIC, fractional
inhibitory concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; OD, optical density; FBS, fetal
bovine serum; NADPH, nicotinamide adenine dinucleotide
phosphate; SAR, structure−activity relationship; C. diﬃcile,
Clostridium diﬃcile; CDI, Clostridium diﬃcile infection; CDAD,
C. diﬃcile-associated diarrhea; MraY, phospho-MurNAc-penta-
peptide translocase (translocase I); WecA, polyprenyl phos-
phate-GlcNAc-1-phosphate transferase; AglH, dolichyl-phos-
phate GlcNAc-1-phosphotransferase; DPAGT1, dolichyl-phos-
phate GlcNAc-1-phosphotransferase 1; CFU, colony-forming
unit; BHI, brain−heart infusion medium; Vero cells, African
green monkey kidney cells; Caco-2 cells, heterogeneous human
epithelial colorectal adenocarcinoma cells; C. perfringens,
Clostridium perfringens; S. aureus, Staphylococcus aureus; B. subtilis,
Bacillus subtilis; S. pneumoniae, Streptococcus pneumoniae; M.
smegmatis,Mycobacterium smegmatis; L. acidophilus, Lactobacillus
acidophilus; L. casei, Lactobacillus casei; F. periodontium,
Fusobacterium periodontium; B. fragilis, Bacteroides fragilis; A.
baumannii, Acinetobacter baumannii; P. aeruginosa, Pseudomonas
aeruginosa; K. pneumoniae, Klebsiella pneumoniae; E. coli,
Escherichia coli
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